Are you Experienced?: Using the lessons learned from marketing research on consumer experience to improve the research and development of new HIV prevention technologies
暂无分享,去创建一个
[1] M. Francis-Chizororo,et al. The female condom: acceptability and perception among rural women in Zimbabwe. , 2003, African journal of reproductive health.
[2] V. Chandeying,et al. Perceptions and acceptability of the female condom [Femidom] amongst commercial sex workers in the Songkla province, Thailand. , 1998, International journal of STD & AIDS.
[3] J. Wijgert,et al. Constraints faced by sex workers in use of female and male condoms for safer sex in urban Zimbabwe , 2001, Journal of Urban Health.
[4] B. Friedland,et al. Men's attitudes towards a potential vaginal microbicide in Zimbabwe, Mexico and the USA , 2000, Reproductive health matters.
[5] A. Carballo-Diéguez,et al. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. , 2008, Journal of women's health.
[6] C. Woodsong. Covert use of topical microbicides: implications for acceptability and use. , 2004, International family planning perspectives.
[7] D. Seal,et al. Heterosexual men's attitudes toward the female condom. , 1999, AIDS education and prevention : official publication of the International Society for AIDS Education.
[8] D. Celentano,et al. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. , 2004, American journal of public health.
[9] G. Green,et al. Female control of sexuality: illusion or reality? Use of vaginal products in south west Uganda. , 2001, Social science & medicine.
[10] E. Tolley,et al. Integrating behavioral and social science research into microbicide clinical trials: challenges and opportunities. , 2006, American journal of public health.
[11] C. Coggins,et al. Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: Where have we been? Where are we going? , 2001, Journal of women's health & gender-based medicine.
[12] M. Ruiz,et al. Assessing Microbicide Acceptability: A Comprehensive and Integrated Approach , 2008, AIDS and Behavior.
[13] C. Woodsong,et al. Two good reasons: women's and men's perspectives on dual contraceptive use. , 1999, Social science & medicine.
[14] Joel Lexchin,et al. The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States , 2008, PLoS medicine.
[15] M. Latka. Female-initiated barrier methods for the prevention of STI/HIV: Where are we now? where should we go? , 2001, Journal of Urban Health.
[16] M. Bassett,et al. Acceptability of the female condom in Zimbabwe: Positive but male-centred responses , 1995 .
[17] K. Mayer,et al. Acceptability of Formulations and Application Methods for Vaginal Microbicides Among Drug‐Involved Women: Results of Product Trials in Three Cities , 2000, Sexually transmitted diseases.
[18] Robert G. Cooper,et al. Winning at new products : accelerating the process from idea to launch , 2001 .
[19] D. Seal,et al. The Female Condom: What We Have Learned Thus Far , 1998, AIDS and Behavior.
[20] Jan Hult. The Itera Plastic Bicycle , 1992 .
[21] A. Mbonye,et al. An acceptability study of female-controlled methods of protection against HIV and STDs in south-western Uganda , 2000, International journal of STD & AIDS.
[22] G. Green,et al. Women's attitudes to condoms and female-controlled means of protection against HIV and STDs in south-western Uganda. , 1999, AIDS care.
[23] J. Mantell,et al. The future of the female condom. , 2004, International family planning perspectives.
[24] D. Shervington. The acceptability of the female condom among low-income African-American women. , 1993, Journal of the National Medical Association.
[25] A. Mbonye,et al. Ambivalence, sexual pleasure and the acceptability of microbicidal products in south-west Uganda. , 2000, AIDS.
[26] N. Chatterjee,et al. Beliefs, sexual behaviours and preventive practices with respect to HIV/AIDS among commercial sex workers in Daulatdia, Bangladesh. , 2005, Public health.